caa a22 4500 475847008 CHVBK 20180406123917.0 cr unu---uuuuu 170329e20000701xx s 000 0 eng 10.1023/A:1008903126315 doi (NATIONALLICENCE)springer-10.1023/A:1008903126315 Patient preferences and utilities for ‘off-time' outcomes in the treatment of Parkinson's disease [Elektronische Daten] [Cynthia Palmer, Jordana Schmier, Edward Snyder, Burton Scott] The purpose of this study was to derive patient preferences and utilities for outcomes associated with treatment of motor fluctuations, or ‘off-time' for patients with Parkinson's disease (PD). Visual analog scale (VAS) and standard gamble (SG) approaches were used with 60 patients to determine patient preferences and utilities for 10 health state descriptions. Health state descriptions were categorized according to two factors: disease severity, and proportion of the day with ‘off-time'. There were two representative levels of disease severity, based on Hoehn and Yahr stages 1.5 and 2.5: unilateral disease with no postural instability, and bilateral disease with some postural instability. These severity levels were combined with five levels of ‘off-time' per day ranging from none to > 75% of the day. Patients' mean preference or utility for their own current health ranged from 0.65 ± 0.20 (VAS) to 0.74 ± 0.22 (SG). Patients assigned the lowest mean values to the health state description for Hoehn and Yahr stage 2.5 with ‘off-time' for > 75% of the day (VAS: 0.17 ± 0.17; SG: 0.49 ± 0.27). The highest mean values were assigned to Hoehn and Yahr stage 1.5 with no ‘off-time' (VAS: 0.83 ± 0.17; SG: 0.85 ± 0.18). The results of this study indicated patients with PD would likely seek treatment that would minimize the amount of ‘off-time' experienced per day, and that patients were relatively risk averse. Kluwer Academic Publishers, 2000 Fluctuations nationallicence Health state utilities nationallicence Parkinson's disease nationallicence Preference measurement nationallicence Quality of life nationallicence Palmer Cynthia MEDTAP International, Bethesda, Maryland aut Schmier Jordana MEDTAP International, Bethesda, Maryland aut Snyder Edward Novartis Pharmaceuticals, East Hanover, NJ aut Scott Burton Duke University Medical Center, Durham, NC aut Quality of Life Research Kluwer Academic Publishers 9/7(2000-07-01), 819-827 0962-9343 9:7<819 2000 9 11136 https://doi.org/10.1023/A:1008903126315 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1008903126315 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Palmer Cynthia MEDTAP International, Bethesda, Maryland aut NATIONALLICENCE 700 1- Schmier Jordana MEDTAP International, Bethesda, Maryland aut NATIONALLICENCE 700 1- Snyder Edward Novartis Pharmaceuticals, East Hanover, NJ aut NATIONALLICENCE 700 1- Scott Burton Duke University Medical Center, Durham, NC aut NATIONALLICENCE 773 0- Quality of Life Research Kluwer Academic Publishers 9/7(2000-07-01), 819-827 0962-9343 9:7<819 2000 9 11136 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer